E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome or Prolymphocytic Leukemia |
chronisch-lymphatische Leukämie (CLL), kleinzellig-lymphozytisches Lymphom (SLL), Richter-Transformation oder Transformation in eine Prolymphozyten-Leukämie |
|
E.1.1.1 | Medical condition in easily understood language |
Leukemia and special types of Leukemia |
Leukämie und Sonderformen der Leukämie |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10073483 |
E.1.2 | Term | B-cell prolymphocytic leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008976 |
E.1.2 | Term | Chronic lymphocytic leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003910 |
E.1.2 | Term | B-cell small lymphocytic lymphoma NOS |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10058728 |
E.1.2 | Term | Richter's syndrome |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• Establish the safety and the MTD of orally administered ACP-196 in subjects with CLL/SLL
• Determine the PK of orally administered ACP-196 and identification of its major metabolite
• Measure PD parameters including drug occupancy of BTK, the target enzyme, and effect on biologic markers of B-cell function |
|
E.2.2 | Secondary objectives of the trial |
• Overall response rate
• Duration of response
• Progression-free survival
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Men and women ≥ 18 years of age with a confirmed diagnosis of CLL/SLL, which has relapsed after, or been refractory to, ≥ 1 previous treatments for CLL/SLL.
• Must have measurable CLL/SLL defined as lymph nodes ≥ 2 cm as measured in the longest diameter.
• Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring treatment:
o Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (hemoglobin < 10 g/dL) and/or thrombocytopenia (platelets < 100,000/μL).
o Massive (ie, ≥ 6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
o Massive nodes (ie, ≥ 10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy.
o Progressive lymphocytosis with an increase of > 50% over a 2-month period or a lymphocyte doubling time (LDT) of < 6 months. LDT may be obtained by linear regression extrapolation of absolute lymphocyte counts (ALC) obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of < 30 X 109/L (30,000/μL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (eg, infections) should be excluded.
o Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy.
o Constitutional symptoms documented in the subject’s chart with supportive objective measures, as appropriate, defined as ≥ 1 of the following disease-related symptoms or signs:
Unintentional weight loss ≥ 10% within the previous 6 months before Screening.
Fevers higher than 100.5°F or 38.0°C for 2 or more weeks before Screening without evidence of infection.
Night sweats for > 1 month before Screening without evidence of infection.
• ECOG performance status of ≤ 2.
• Agreement to use contraception during the study and for 30 days after the last dose of study drug if sexually active and able to bear or beget children (eg, condoms, implants, injectables, combined oral contraceptives, intrauterine devices [IUDs], true sexual abstinence [Please note that periodic abstinence, eg, calendar, ovulation, symptothermal, post-ovulation methods, and withdrawal are not acceptable methods of contraception], or sterilized partner).
• Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
• Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations).
• Male subjects must agree to refrain from sperm donation during the study and for 30 days after the last dose of study drug.
• Treatment Naive only: Men and women ≥ 18 years of age with confirmed diagnosis of CLL/SLL, who require treatment per National Cancer Institute (NCI) or International Working Group guidelines and a) do not want to receive chemoimmunotherapy or b) have comorbidities that would preclude chemoimmunotherapy.
• Ibrutinib Intolerant only: Men and women ≥ 18 years of age with confirmed diagnosis of CLL/SLL who are not tolerating ibrutinib due to ibrutinib-related AEs.
• Richter’s Syndrome/Prolymphocytic Leukemia Transformation only: Men and women ≥ 18 years of age and biopsy proven DLBCL Richter's transformation or prolymphocytic leukemia transformation.
• Ibrutinib R/R only: Men and women ≥ 18 years of age with confirmed diagnosis of CLL/SLL whose best response after 2 cycles of ibrutinib therapy was SD or nonresponse or who initially responded to ibrutinib therapy and now have signs of clinical progression.
|
|
E.4 | Principal exclusion criteria |
• Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to < 2 years. Note: these cases must be discussed with the Medical Monitor.
• A life-threatening illness, medical condition or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ACP-196, or put the study outcomes at undue risk.
• Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) ≤ 40%.
• Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
• Any immunotherapy within 4 weeks of first dose of study drug.
• For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after 5 times the half-life of the agent(s).
• Relapsed after, or refractory to, prior Btk inhibitor therapy (Note: Does not apply to Ibrutinib R/R Group).
• Any history of Richter's transformation (Note: Does not apply to Richter’s Syndrome or Ibrutinib R/R Groups).
• Concomitant use of medicines known to cause QT prolongation or Torsades de pointes (see Appendix 1).
• Central nervous system (CNS) involvement by lymphoma.
• Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation.
• Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection.
• Uncontrolled AIHA or ITP defined as declining hemoglobin or platelet count secondary to autoimmune destruction within the screening period or requirement for high doses of steroids (> 20 mg daily of prednisone daily or equivalent).
• History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug.
• Requires treatment with a long-acting proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).
• Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 28 days of first dose of study drug.
• Major surgery within 4 weeks before first dose of study drug.
• ANC < 0.75 x 109/L or platelet count < 50 x 109/L unless there is bone marrow involvement.
• Creatinine > 1.5 x institutional upper limit of normal (ULN); total bilirubin > 1.5 x ULN (total bilirubin ≤ 2.5 x ULN allowed in subjects with autoimmune hemolytic anemia that is otherwise controlled); and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3.0 x ULN unless disease related.
• Serum amylase > 1.5 x ULN or serum lipase > 1.5 x ULN.
• Significant screening ECG abnormalities including, 2nd degree AV block type II, 3rd degree block, atrial fibrillation, Grade 2 or higher bradycardia, and QTc ≥ 480 ms.
• Cardiac troponin I levels above the limit of normal as specified by the manufacturer.
• Breast feeding or pregnant.
• History of bleeding diathesis (eg, hemophilia, von Willebrand disease).
• Concurrent participation in another therapeutic clinical trial.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy Parameters
• Overall response rate
• Duration of response
• Progression-free survival
Safety Parameters
• DLTs and MTD
• Frequency, severity, and attribution of adverse events (AEs)
Pharmacokinetic and Pharmacodynamic Parameters
The occupancy of BTK by ACP-196 will be measured in peripheral blood
mononuclear cells (PBMCs) with the aid of a biotin-tagged ACP-196 analogue
probe. The effect of ACP-196 on biologic markers of B-cell function will also be
evaluated. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
> 28 days until disease progression or an unacceptable drug-related toxicity occurs |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Sequential Dose Escalation |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 11 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 3 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Germany |
Italy |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |